Nexalis Therapeutics

Nexalis Therapeutics is a biotechnology company pioneering the development of Covalent Molecular Linkers (CMLs) to treat cancer and autoimmune diseases. The company's platform focuses on induced proximity, using small molecules to create permanent, covalent bonds between a target protein and a functional effector protein. This approach allows for the modulation of previously "undruggable" targets with high specificity and durability. By expanding the reach of proximity-based therapeutics beyond traditional degradation, Nexalis aims to unlock new mechanisms of action for complex diseases. Headquartered in San Diego, the company was founded and seeded by Versant Ventures through its Ridgeline Discovery Engine. Nexalis is currently advancing a pipeline of pre-clinical candidates designed to address significant unmet needs in oncology and immunology.